Who are Oxiamin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Isoprinosin, Mycophénolate Mofétil, Mycophenolate mofetil Tablet/Capsule, Mycophenolate Na, Myfortic plus low-dose steroid, Myfortic Escalation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inosine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Oxiamin — Competitive Intelligence Brief

Oxiamin (INOSINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inosine. Area: Cardiovascular.

marketed inosine Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Oxiamin (INOSINE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Oxiamin TARGET	INOSINE		marketed	inosine
Isoprinosin	INOSINE PRANOBEX		marketed	inosine pranobex
Mycophénolate Mofétil	Mycophénolate Mofétil	University Hospital, Limoges	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor	IMPDH type II
Mycophenolate mofetil Tablet/Capsule	Mycophenolate mofetil Tablet/Capsule	Chong Kun Dang Pharmaceutical	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor; immunosuppressant	IMPDH type II (inosine monophosphate dehydrogenase)
Mycophenolate Na	Mycophenolate Na	Sanofi	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor	IMPDH type II
Myfortic plus low-dose steroid	Myfortic plus low-dose steroid	The University of Hong Kong	marketed	Immunosuppressant (inosine monophosphate dehydrogenase inhibitor)	Inosine monophosphate dehydrogenase (IMPDH), type II
Myfortic Escalation	Myfortic Escalation	East Carolina University	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor	IMPDH type II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inosine class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxiamin — Competitive Intelligence Brief. https://druglandscape.com/ci/inosine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab